Bimekizumab in PsA Showed Sustained Reductions in Disease Impact Save
Dr. Eric Dein talks with Dr. Ana-Marie Orbai about abstract 0600, Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Reductions in Disease Impact Assessed by the Psoriatic Arthritis Impact of Disease (PsAID)-12 Questionnaire: Up to 2‑Year Results from Two Phase 3 Studies, presented at the 2024 ACR Convergence meeting in Washington, DC.
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.